Delving into the Latest Updates on Nextgen Bioscience Co., Ltd. with Synapse

Overview

Tags

Respiratory Diseases

Congenital Disorders

Eye Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2

Top 5 Drug Type	Count

Small molecule drug	10

Top 5 Target	Count

HIF-1α(Hypoxia-inducible factor 1 alpha)	1
S1PRs(Sphingosine 1-phosphate receptors)	1
autotaxin(Ectonucleotide pyrophosphatase/phosphodiesterase 2)	1

Author: Koh, Eun Hee ; Kim, Jae Hyun ; Lee, Seung Eun ; Cho, Yun Kyung ; Choi, Ji Woong ; Kim, Sanghee ; Fernandez-Checa, Jose ; Lee, Ki-Up ; Yoon, Ji Eun ; Lee, Chi-Ho ; Oh, Soo Jin ; Baek, Ji Yeon ; Yun, Ji-Young ; Baek, In-Jeoung ; Jang, Jung Eun ; Lee, Jongkook ; Lim, Joon Seo ; Lee, Bong Yong ; Hartig, Sean ; Hong, Chung Hwan ; Cho, Hyunkyung ; Ko, Myoung Seok

AbstractSphingosine 1-phosphate (S1P) receptors (S1PRs) are a group of G protein-coupled receptors that confer a broad range of functional effects in chronic inflammatory diseases and metabolic diseases. S1PRs may also be involved in the development of non-alcoholic steatohepatitis (NASH), but the specific subtypes involved and the mechanism of action are unclear. Here we show that the livers of various mouse models of NASH as well as Kupffer cells had a particularly strong expression of S1pr4. Accordingly, genetic depletion of S1pr4 protected the mice against hepatic inflammation and fibrosis. Moreover, SLB736, a novel selective functional antagonist of SIPR4 prevented diet-induced NASH in mice without lymphopenia. S1P increased the expression of S1pr4 in Kupffer cells and activated the NLRP3 inflammasome through PLC/IP3/IP3R-dependent [Ca++] signaling. SLB736 treatment or S1pr4 depletion in Kupffer cells inhibited LPS-mediated Ca++ release and deactivated the NLRP3 inflammasome. S1PR4 antagonism may be a novel therapeutic strategy for NASH.

100 Deals associated with Nextgen Bioscience Co., Ltd.

Login to view more data

100 Translational Medicine associated with Nextgen Bioscience Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

4

Preclinical

Phase 2 Clinical

1

5

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

NXC-736 ( S1PRs )	Alopecia Areata More	Phase 2
NCL-920	Pulmonary Fibrosis More	Preclinical
NXC-828 ( HIF-1α )	Wet age-related macular degeneration More	Preclinical
NXC-680 ( autotaxin )	Idiopathic Pulmonary Fibrosis More	Preclinical
NX-2101	Autoimmune Diseases More	Preclinical